Skip to main content

Table 1 FONT I: Clinical and laboratory features

From: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

 

Result

Age (yr)

16.0 ± 7.5

Pubertal status (<Tanner 3:≥ Tanner 3)

9:12

Gender (M:F)

12:9

Ethnicity (White:Black:Hispanic:Other)

11:5:2:3

Ht (cm)

151 ± 24

Wt (kg)

54 ± 25

Up:cr (mg:mg)

9.3 ± 8.8

GFRe (ml/min/1.73 m2)

121 ± 56